Sage Therapeutics shares dropped early Wednesday after the company said its experimental treatment for mild cognitive impairment in patients with Parkinson’s disease fell flat in a clinical trial.
More Stories
Investors cheer a soft landing scenario after Fed’s big rate cut. But they’re still keeping their guard up for a downturn.
The Federal Reserve finally gave stock-market investors what they wanted this week by cutting interest rates for the first time...
As third-quarter earnings approach, here are the stocks that analysts like — and dislike — the most
This summer, shares of Amazon.com Inc., Microsoft Corp. and Nvidia Corp. each took a hit after the technology giants reported...
CDs paying 5% are a dying breed. Here’s how to find high savings rates while you still can.
Many 5% CDs are going away in the weeks after the Fed’s first interest-rate cut. Some have already disappeared.
Stocks poised for first September gain in 5 years. Why more good times could lie ahead.
September has historically been the worst month for U.S. stocks — but not this year
This mortgage hack could save you thousands a year — and it’s not a refinance
Homeowners looking to leverage lower mortgage rates can ask their lenders for a “rate modification,” financial experts say.